Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2015

01-06-2015 | Article

Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin

Authors: J. R. Costa, N. C. Silva, B. Sarmento, M. Pintado

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2015

Login to get access

Abstract

Daptomycin may offer an antibacterial alternative for the treatment of endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA) and other potential agents. In the present project, mucoadhesive chitosan-coated alginate (CS-ALG) nanoparticles are proposed as an effective delivery system for daptomycin permeation across ocular epithelia, with potential for the treatment of bacterial endophthalmitis. CS-ALG nanoparticles were prepared by ionotropic pre-gelation of an alginate core followed by chitosan polyelectrolyte complexation, and characterized regarding particle size, polydispersity, and zeta potential. The encapsulation efficiency was determined and antimicrobial activity was also tested after encapsulation of the antibiotic. Also, in vitro ocular permeability of free daptomycin and encapsulation into chitosan and CS-ALG nanoparticles was evaluated using ocular epithelial cell culture models. Formulated daptomycin-loaded CS-ALG nanoparticles were negatively charged, with a size range of 380–420 nm, suitable for ocular application. The encapsulation efficiency was between 79 and 92 %, with decreasing alginate:daptomycin mass ratios. The antibacterial activity of daptomycin against major microorganisms responsible for bacterial endophthalmitis was not affected by encapsulation into nanoparticles. Daptomycin permeability was up to 16 % (chitosan nanoparticles) and 9 % (CS-ALG nanoparticles) through corneal cell monolayer, and 18 % (chitosan nanoparticles) and 12 % (CS-ALG nanoparticles) for retinal cell monolayer after 4 h, demonstrating epithelial retention of the drug compared to free drug. The developed daptomycin-loaded CS-ALG nanoparticles seem to be an interesting and potential system for ocular daptomycin delivery and treatment of bacterial endophthalmitis.
Literature
1.
go back to reference Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS (2002) Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium–host interactions. Clin Microbiol Rev 15:111–124CrossRefPubMedCentralPubMed Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS (2002) Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium–host interactions. Clin Microbiol Rev 15:111–124CrossRefPubMedCentralPubMed
2.
go back to reference Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Rao TN (1999) Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol 128:240–242CrossRefPubMed Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Rao TN (1999) Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol 128:240–242CrossRefPubMed
3.
go back to reference Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD (2007) Bacterial endophthalmitis: therapeutic challenges and host–pathogen interactions. Prog Retin Eye Res 26:189–203CrossRefPubMedCentralPubMed Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD (2007) Bacterial endophthalmitis: therapeutic challenges and host–pathogen interactions. Prog Retin Eye Res 26:189–203CrossRefPubMedCentralPubMed
4.
go back to reference Jeu L, Fung HB (2004) Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26:1728–1757CrossRefPubMed Jeu L, Fung HB (2004) Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26:1728–1757CrossRefPubMed
6.
go back to reference Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–1135CrossRefPubMed Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–1135CrossRefPubMed
7.
go back to reference de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ (2010) Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62:100–117CrossRefPubMed de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ (2010) Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62:100–117CrossRefPubMed
8.
9.
go back to reference Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK (2008) Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 68:513–525PubMed Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK (2008) Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 68:513–525PubMed
10.
go back to reference Nagarwal RC, Kumar R, Pandit JK (2012) Chitosan coated sodium alginate–chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 47:678–685CrossRefPubMed Nagarwal RC, Kumar R, Pandit JK (2012) Chitosan coated sodium alginate–chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 47:678–685CrossRefPubMed
11.
go back to reference Yan XL, Khor E, Lim LY (2001) Chitosan–alginate films prepared with chitosans of different molecular weights. J Biomed Mater Res 58:358–365CrossRefPubMed Yan XL, Khor E, Lim LY (2001) Chitosan–alginate films prepared with chitosans of different molecular weights. J Biomed Mater Res 58:358–365CrossRefPubMed
12.
go back to reference de Campos AM, Diebold Y, Carvalho ELS, Sánchez A, Alonso MJ (2004) Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803–810CrossRefPubMed de Campos AM, Diebold Y, Carvalho ELS, Sánchez A, Alonso MJ (2004) Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803–810CrossRefPubMed
13.
go back to reference Liu W, Griffith M, Li F (2008) Alginate microsphere–collagen composite hydrogel for ocular drug delivery and implantation. J Mater Sci Mater Med 19:3365–3371CrossRefPubMed Liu W, Griffith M, Li F (2008) Alginate microsphere–collagen composite hydrogel for ocular drug delivery and implantation. J Mater Sci Mater Med 19:3365–3371CrossRefPubMed
14.
15.
go back to reference Sangeetha S, Venkatesh DN, Adhiyaman R, Santhi K, Suresh B (2007) Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop J Pharm Res 6:653–659CrossRef Sangeetha S, Venkatesh DN, Adhiyaman R, Santhi K, Suresh B (2007) Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop J Pharm Res 6:653–659CrossRef
16.
go back to reference Ding S (1998) Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1:328–335CrossRef Ding S (1998) Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1:328–335CrossRef
17.
go back to reference Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136:2–13CrossRefPubMed Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136:2–13CrossRefPubMed
18.
go back to reference Mi FL, Tan YC, Liang HF, Sung HW (2002) In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23:181–191CrossRefPubMed Mi FL, Tan YC, Liang HF, Sung HW (2002) In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23:181–191CrossRefPubMed
19.
go back to reference Tamboli V, Mishra GP, Mitra AK (2012) Biodegradable polymers for ocular drug delivery. Adv Ocul Drug Deliv 2012:65–86 Tamboli V, Mishra GP, Mitra AK (2012) Biodegradable polymers for ocular drug delivery. Adv Ocul Drug Deliv 2012:65–86
20.
go back to reference Severino P, Vasconcellos FC, Figueiredo ES (2007) Uso tópico de quitosana em oftalmologia. Rev Bras Farm 88:155–158 Severino P, Vasconcellos FC, Figueiredo ES (2007) Uso tópico de quitosana em oftalmologia. Rev Bras Farm 88:155–158
21.
go back to reference Mourya VK, Inamdar NN (2008) Chitosan-modifications and applications: opportunities galore. React Funct Polym 68:1013–1051CrossRef Mourya VK, Inamdar NN (2008) Chitosan-modifications and applications: opportunities galore. React Funct Polym 68:1013–1051CrossRef
22.
go back to reference Subramanian A, Vasanthan KS, Krishnan UM, Sethuraman S (2011) Chitosan and its derivatives in clinical use and applications. In: Domb AJ, Kumar N, Ezra A (eds) Biodegradable polymers in clinical use and clinical development. Wiley, New Jersey, pp 113–135 Subramanian A, Vasanthan KS, Krishnan UM, Sethuraman S (2011) Chitosan and its derivatives in clinical use and applications. In: Domb AJ, Kumar N, Ezra A (eds) Biodegradable polymers in clinical use and clinical development. Wiley, New Jersey, pp 113–135
23.
go back to reference Zahoor A, Sharma S, Khuller GK (2005) Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26:298–303 Zahoor A, Sharma S, Khuller GK (2005) Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26:298–303
24.
go back to reference Sarmento B, Ribeiro A, Veiga F, Ferreira D (2006) Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr 20:898–903CrossRefPubMed Sarmento B, Ribeiro A, Veiga F, Ferreira D (2006) Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr 20:898–903CrossRefPubMed
25.
go back to reference Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D (2007) Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24:2198–2206CrossRefPubMed Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D (2007) Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24:2198–2206CrossRefPubMed
26.
go back to reference Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, NCCLS document M7-A6, 6th edition. Villanova, Pennsylvania, USA Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, NCCLS document M7-A6, 6th edition. Villanova, Pennsylvania, USA
27.
go back to reference Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing, 15th informational supplement, NCCLS document M100-S15. Villanova, Pennsylvania, USA Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing, 15th informational supplement, NCCLS document M100-S15. Villanova, Pennsylvania, USA
28.
go back to reference Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155–169CrossRefPubMed Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155–169CrossRefPubMed
29.
go back to reference Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y (2009) Ocular drug delivery impact of in vitro cell culture models. J Ophthalmic Vis Res 4:238–252PubMedCentralPubMed Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y (2009) Ocular drug delivery impact of in vitro cell culture models. J Ophthalmic Vis Res 4:238–252PubMedCentralPubMed
30.
go back to reference Geiger RC, Waters CM, Kamp DW, Glucksberg MR (2005) KGF prevents oxygen-mediated damage in ARPE-19 cells. Invest Ophthalmol Vis Sci 46:3435–3442CrossRefPubMed Geiger RC, Waters CM, Kamp DW, Glucksberg MR (2005) KGF prevents oxygen-mediated damage in ARPE-19 cells. Invest Ophthalmol Vis Sci 46:3435–3442CrossRefPubMed
31.
go back to reference Zimmer A, Kreuter J (1995) Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 16:61–73CrossRef Zimmer A, Kreuter J (1995) Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 16:61–73CrossRef
32.
go back to reference Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–327CrossRef Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–327CrossRef
33.
go back to reference Chen A, Haddad D, Wang R (2009) Analysis of chitosan-alginate bone scaffolds. Rutgers University, New Jersey Governor’s School of Engineering & Technology Chen A, Haddad D, Wang R (2009) Analysis of chitosan-alginate bone scaffolds. Rutgers University, New Jersey Governor’s School of Engineering & Technology
34.
go back to reference Harnsilawat T, Pongsawatmanit R, McClements DJ (2006) Characterization of β-lactoglobulin–sodium alginate interactions in aqueous solutions: a calorimetry, light scattering, electrophoretic mobility and solubility study. Food Hydrocoll 20:577–585CrossRef Harnsilawat T, Pongsawatmanit R, McClements DJ (2006) Characterization of β-lactoglobulin–sodium alginate interactions in aqueous solutions: a calorimetry, light scattering, electrophoretic mobility and solubility study. Food Hydrocoll 20:577–585CrossRef
35.
go back to reference Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58:1423–1430CrossRef Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58:1423–1430CrossRef
36.
go back to reference Barry AL, Fuchs PC, Brown SD (2001) In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45:1919–1922CrossRefPubMedCentralPubMed Barry AL, Fuchs PC, Brown SD (2001) In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45:1919–1922CrossRefPubMedCentralPubMed
37.
go back to reference Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49:467–470CrossRefPubMed Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49:467–470CrossRefPubMed
38.
go back to reference Fluit AC, Schmitz FJ, Verhoef J, Milatovic D (2004) In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 48:1007–1011CrossRefPubMedCentralPubMed Fluit AC, Schmitz FJ, Verhoef J, Milatovic D (2004) In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 48:1007–1011CrossRefPubMedCentralPubMed
39.
go back to reference Hornof M, Toropainen E, Urtti A (2005) Cell culture models of the ocular barriers. Eur J Pharm Biopharm 60:207–225CrossRefPubMed Hornof M, Toropainen E, Urtti A (2005) Cell culture models of the ocular barriers. Eur J Pharm Biopharm 60:207–225CrossRefPubMed
40.
go back to reference Mannermaa E, Reinisalo M, Ranta V-P, Vellonen K-S, Kokki H, Saarikko A, Kaarniranta K, Urtti A (2010) Filter-cultured ARPE-19 cells as outer blood–retinal barrier model. Eur J Pharm Sci 40:289–296CrossRefPubMed Mannermaa E, Reinisalo M, Ranta V-P, Vellonen K-S, Kokki H, Saarikko A, Kaarniranta K, Urtti A (2010) Filter-cultured ARPE-19 cells as outer blood–retinal barrier model. Eur J Pharm Sci 40:289–296CrossRefPubMed
41.
go back to reference Nagai N, Ito Y, Okamoto N, Shimomura Y (2014) A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 319:53–62CrossRefPubMed Nagai N, Ito Y, Okamoto N, Shimomura Y (2014) A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 319:53–62CrossRefPubMed
42.
go back to reference Antunes F, Andrade F, Araújo F, Ferreira D, Sarmento B (2013) Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 83:427–435CrossRefPubMed Antunes F, Andrade F, Araújo F, Ferreira D, Sarmento B (2013) Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 83:427–435CrossRefPubMed
43.
go back to reference Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609CrossRefPubMed Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609CrossRefPubMed
44.
go back to reference De Campos AM, Sánchez A, Alonso MJ (2001) Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 224:159–168CrossRefPubMed De Campos AM, Sánchez A, Alonso MJ (2001) Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 224:159–168CrossRefPubMed
Metadata
Title
Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin
Authors
J. R. Costa
N. C. Silva
B. Sarmento
M. Pintado
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2344-7

Other articles of this Issue 6/2015

European Journal of Clinical Microbiology & Infectious Diseases 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.